A Binding Site for Nonsteroidal Anti-inflammatory Drugs in Fatty Acid Amide Hydrolase
Journal of the American Chemical Society2012Vol. 135(1), pp. 22–25
Citations Over TimeTop 10% of 2012 papers
Laura Bertolacci, Elisa Romeo, Marina Veronesi, Paola Magotti, Clara Albani, Mauro Dionisi, Chiara Lambruschini, Rita Scarpelli, Andrea Cavalli, Marco De Vivo, Daniele Piomelli, G. Garau
Abstract
In addition to inhibiting the cyclooxygenase (COX)-mediated biosynthesis of prostanoids, various widely used nonsteroidal anti-inflammatory drugs (NSAIDs) enhance endocannabinoid signaling by blocking the anandamide-degrading membrane enzyme fatty acid amide hydrolase (FAAH). The X-ray structure of FAAH in complex with the NSAID carprofen, along with site-directed mutagenesis, enzyme activity assays, and NMR analysis, has revealed the molecular details of this interaction, providing information that may guide the design of dual FAAH-COX inhibitors with superior analgesic efficacy.
Related Papers
- → Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system(2003)301 cited
- → Alterations in the Endocannabinoid System in Schizophrenia(2020)2 cited
- → Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents: An Update(2004)
- → Natural Endocannabinoid Derivatives as Templates for the Development of FAAH Inhibitors(2005)
- → Fatty acid amide hydrolase, anandamide, and neurological diseases(2023)